Testosterone Injections – Free New Step By Step Guide From Secrets of Bodybuilding
24 févr. 2022 10h00 HE
|
Secrets Of Bodybuilding
VENICE, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Bodybuilding trainer, and award winning bodybuilding blogger Victor Brock has produced a new free step by step testosterone injections...
Clarus Therapeutics Appoints Dr. Zhanna Jumadilova as Chief Clinical Development Officer
18 janv. 2022 09h05 HE
|
Clarus Therapeutics Holdings, Inc.
Dr. Jumadilova most recently led clinical development programs at Insmed and Pfizer and has nearly 30 years of combined pharmaceutical and biotech experience NORTHBROOK, Ill., Jan. 18, 2022 (GLOBE...
Global Endocrine Function Testing Industry Report 2022-2026 Featuring Profiles of Abbott Labs, bioMerieux, Bio-Rad, Grifols, PerkinElmer, Roche, Siemens Healthineers, Thermo Fisher, and More
17 déc. 2021 08h13 HE
|
Research and Markets
Dublin, Dec. 17, 2021 (GLOBE NEWSWIRE) -- The "2022-2026 World Endocrine Function Testing Market - Supplier Shares, Forecasts for 20 Tests, Opportunities in 97 Countries - Growth Strategies, Volume...
Clarus Therapeutics Announces Closing of Approximately $15 Million Private Placement
07 déc. 2021 16h05 HE
|
Clarus Therapeutics Holdings, Inc.
Proceeds to support the ongoing commercialization of JATENZO® (testosterone undecanoate) NORTHBROOK, Ill., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus)...
Clarus Therapeutics Announces $15 Million Private Placement
03 déc. 2021 09h05 HE
|
Clarus Therapeutics Holdings, Inc.
Proceeds to support the ongoing commercialization of JATENZO® (testosterone undecanoate) NORTHBROOK, Ill., Dec. 03, 2021 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus)...
Clarus Therapeutics Announces Issuance of Two New Patents for JATENZO® (testosterone undecanoate)
30 nov. 2021 09h05 HE
|
Clarus Therapeutics Holdings, Inc.
JATENZO is the first and only FDA-approved oral softgel for testosterone replacement therapy (TRT) in adult males who have deficient testosterone due to certain medical conditions Clarus plans to...
Clarus Therapeutics Reports Third Quarter 2021 Financial and Operating Results
18 nov. 2021 16h05 HE
|
Clarus Therapeutics Holdings, Inc.
Third quarter 2021 revenue increased 93% year-over-year to $4.3 million Third quarter 2021 total prescription growth for JATENZO® increased 12% sequentially and 132% year-over-year Conference call...
Clarus Therapeutics Announces Two Notices of Allowance for Patent Claims Covering JATENZO® (testosterone undecanoate)
26 oct. 2021 09h05 HE
|
Clarus Therapeutics Holdings, Inc.
JATENZO® (testosterone undecanoate) is the first and only FDA-approved oral softgel for testosterone replacement therapy (TRT) in adult males who have deficient testosterone due to certain medical...
Clarus Therapeutics to Present New Real-World Experience Data for JATENZO® (testosterone undecanoate) at the 22nd Annual Fall Scientific Meeting of SMSNA
14 oct. 2021 09h05 HE
|
Clarus Therapeutics Holdings, Inc.
JATENZO® (testosterone undecanoate) is the first and only FDA-approved oral softgel for testosterone replacement therapy (TRT) in adult males who have deficient testosterone due to certain medical...
Clarus Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
15 sept. 2021 09h05 HE
|
Clarus Therapeutics Holdings, Inc.
NORTHBROOK, Ill., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Nasdaq:CRXT), a specialty pharmaceutical company dedicated to providing solutions to unmet medical needs by...